Provident Financial Services Inc. Annual stock financials by MarketWatch. View the latest PFS financial statements, income statements and financial ratios.
Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518 In this ...
Late-breaking results from the Phase III NRG GY019 trial indicate that letrozole monotherapy (L) did not demonstrate ...
Regulatory Challenges: Is a Surrogate End Point Instead of Overall Survival Enough for Regulatory Approval of (Neo)Adjuvant Cancer Treatment? The Swissmedic Perspective PFS depends on evaluation of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results